重症肌无力(myasthenia gravis,MG)是一种主要由抗体介导且累及神经肌肉接头的自身免疫疾病,该病自发缓解率低,治疗主要以免疫抑制及清除抗体为主。近年来随着临床和实验研究的深入,认为病毒持续感染、遗传因素和免疫应答异常与MG的发生密切相关。在病因方面一般认为外因如Epstein-Barr(EB)病毒感染通过内因起作用,为治疗开拓了新思路[1]。肌肉特异性激酶抗体(Mu SK-Ab)及近2年低密度脂蛋白受体相关蛋白4抗体(LRP4-Ab)在该病患者体 Myasthenia gravis (MG) is an autoimmune disease mainly mediated by antibodies and involving the neuromuscular junction. The spontaneous remission rate of this disease is low, and the treatment mainly consists of immunosuppression and antibody clearance. In recent years, with the deepening of clinical and experimental studies, that persistent virus infection, genetic factors and abnormal immune response and the occurrence of MG is closely related. In terms of etiology, it is generally believed that external factors such as Epstein-Barr (EB) virus infection play a role in the treatment through internal factors. Muscle-specific kinase antibody (Mu SK-Ab) and the recent 2 years of low density lipoprotein receptor associated protein 4 antibody (LRP4-Ab) in the patient’s body